Kruszynska YT, Home PD, Hanning I, Alberti KG. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia. 1987;30(1):16-21.
Nosek K, Roggen K, Heinemann L, et al. Insulin aspart has a shorter duration of action than human insulin over a wide dose-range. Diabetes Obes Metab. 2013;15(1):77-83.
Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;(6):CD012161.
Rys P, Pankiewicz O, Lach K, et al. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab. 2011;37(3):190-200.
Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet Med. 2004;2:171-5.
Scognamiglio R, Negut C, de Kreutzenberg SV, et al. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care. 2006;29(1):95-100.
Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of meta-analysis. Diabet Med. 2003;20(10):863-6.
Andersen G, Meiffren G, Lamers D, et al. Ultra-rapid biochaperone lispro improves post-prandial blood glucose excursions versus insulin lispro in a 14-day crossover treatment study in patients with type 1 diabetes. Diabetes Obes Metab. 2018 Jun 19 [epub ahead of print].
Kapitza C, Leohr J, Liu R, et al. A novel formulation of insulin lispro containing citrate and treprostinil shows significantly faster absorption and an improvement in postprandial glucose excursions vs. humalog in patients with T2D. Diabetes. 2017;66(Suppl.1):A253–A254. abstract 978-P.
Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamics characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56(5):551-9.
Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40(7):943-50.
Bowering K, Case C, Harvey J, et al. Faster aspart versus insulin aspart as part of basal-bolus regimen in inadequately controlled type 2 diabetes: The onset 2 trial. Diabetes Care. 2017;40(7):951-7.
Present disclosure: The presenter reported that he has received research funds from Adocia, Boehringer Ingelheim, Dance Pharmaceuticals, Eli Lilly, Johnson & Johnson, Medimmune, MSD, Mylan, Nordic Bioscience, Novo Nordisk, Poxel, Roche Diagnostics, Saniona, Sanofi, Senseonics, and Zealand Pharma. He has also been a member of advisory panels for Novo Nordisk and Mylan. He has received speaker honoraria and travel grants from Dexcom, Eli Lilly, Mylan, Novo Nordisk, Sanofi, and Zealand Pharma.
